Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Open in Screener

ROIV

Roivant Sciences Ltd

Oct 23 • 10:21AM ET

11.61

Dollar change -0.12
Percentage change -1.02	%

Healthcare • Biotechnology • United Kingdom • NASD

Peers: VRTX REGN BIIB BMRN ALNY CRSP INCY NBIX IONS EDIT

| Held by: VTI IJH VB XBI VXF VBK XMHQ MDY IBB FXH

Index	-	P/E	2.08	EPS (ttm)	5.57	Insider Own	49.13%	Shs Outstand	806.68M	Perf Week	-3.01%
Market Cap	8.59B	Forward P/E	-	EPS next Y	-1.09	Insider Trans	-2.20%	Shs Float	376.18M	Perf Month	-0.68%
Income	4.74B	PEG	-	EPS next Q	-0.23	Inst Own	61.94%	Short Float	13.62%	Perf Quarter	8.10%
Sales	158.30M	P/S	54.24	EPS this Y	-114.15%	Inst Trans	4.96%	Short Ratio	8.64	Perf Half Y	6.51%
Book/sh	7.35	P/B	1.58	EPS next Y	-47.19%	ROA	109.72%	Short Interest	51.22M	Perf Year	35.08%
Cash/sh	7.69	P/C	1.51	EPS next 5Y	-	ROE	149.26%	52W Range	8.24 - 13.06	Perf YTD	3.38%
Dividend Est.	-	P/FCF	-	EPS past 5Y	0.08%	ROI	81.76%	52W High	-11.07%	Beta	1.24
Dividend TTM	-	Quick Ratio	27.75	Sales past 5Y	493.24%	Gross Margin	82.02%	52W Low	40.81%	ATR (14)	0.26
Dividend Ex-Date	-	Current Ratio	27.91	EPS Y/Y TTM	541.27%	Oper. Margin	-661.14%	RSI (14)	47.19	Volatility	1.90% 2.26%
Employees	908	Debt/Eq	0.07	Sales Y/Y TTM	101.44%	Profit Margin	2991.76%	Recom	1.17	Target Price	16.94
Option/Short	Yes / Yes	LT Debt/Eq	0.07	EPS Q/Q	131.72%	Payout	0.00%	Rel Volume	0.32	Prev Close	11.73
Sales Surprise	79.47%	EPS Surprise	149.32%	Sales Q/Q	154.96%	Earnings	Aug 08 BMO	Avg Volume	5.93M	Price	11.61
SMA20	0.05%	SMA50	-1.39%	SMA200	4.66%	Trades		Volume	327,822	Change	-1.02%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-15-24	Initiated	Wolfe Research	Outperform	$17
Jan-05-24	Initiated	Piper Sandler	Overweight	$20
Dec-12-23	Initiated	Deutsche Bank	Buy	$14
Oct-17-23	Initiated	Guggenheim	Buy	$17
Jun-08-23	Initiated	BofA Securities	Neutral	$10.50
Oct-27-22	Initiated	JP Morgan	Overweight	$7
May-23-22	Initiated	SVB Leerink	Outperform	$6
Apr-29-22	Initiated	Cantor Fitzgerald	Overweight	$15
Dec-15-21	Initiated	Goldman	Buy	$15
Nov-08-21	Initiated	H.C. Wainwright	Buy	$14
Oct-28-21	Initiated	Citigroup	Buy	$11
Oct-26-21	Initiated	Truist	Buy	$15
Oct-26-21	Initiated	Jefferies	Buy	$10
Oct-26-21	Initiated	Cowen	Outperform

Show Previous Ratings

Sep-18-24 07:30AM	Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA (tapinarof) Cream, 1% (GlobeNewswire)
Sep-10-24 06:30AM	Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator (GlobeNewswire)
06:30AM	Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress (GlobeNewswire)
Sep-09-24 07:00AM	Roivant Provides Update on Graves' Disease Development Program (GlobeNewswire)
Sep-04-24 06:55PM	The Federal Reserve should refresh its mandate: Former presidential candidate Vivek Ramaswamy (Yahoo Finance)
07:00AM	Loading…
Aug-08-24 07:00AM	Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update (GlobeNewswire) +6.69%
Jul-25-24 04:05PM	Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024 (GlobeNewswire)
May-31-24 08:04AM	Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2023 Earnings Call Transcript (Insider Monkey)
May-30-24 11:53AM	ROIV Stock Earnings: Roivant Sciences Beats EPS, Misses Revenue for Q4 2024 (InvestorPlace)
08:20AM	Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update (GlobeNewswire)
May-27-24 06:28PM	Institutional Investors are Betting on Roivant Sciences (NASDAQ:ROIV) (Insider Monkey)
06:13PM	7 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
May-16-24 04:05PM	Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024 (GlobeNewswire)
May-08-24 02:43AM	Greenlight Capital Initiated a Position in Roivant Sciences (ROIV) in Q1 (Insider Monkey)
02:04PM	Loading…
May-07-24 02:04PM	Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare (InvestorPlace)
May-01-24 10:47AM	3 Healthcare Stocks With the Potential to Triple Your Investment by 2026 (InvestorPlace)
Apr-25-24 08:00AM	Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis (Business Wire)
Apr-12-24 11:09AM	10 Most Undervalued Stocks to Buy for Under $20 (Insider Monkey)
Apr-02-24 07:00AM	Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million (GlobeNewswire)
Mar-27-24 01:55PM	Stocks to Watch Wednesday: Carnival, Robinhood, Trump Media, Merck (The Wall Street Journal) +7.54%
Mar-26-24 06:22PM	Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600 (PR Newswire)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-14-24 07:04AM	10 Stocks George Soros and Insiders Are Crazy About (Insider Monkey)
Feb-15-24 02:45AM	Do You Think the Management of Roivant Sciences (ROIV) Can Create Value? (Insider Monkey)
Feb-13-24 07:00AM	Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update (GlobeNewswire)
Feb-10-24 02:55AM	Roivant Sciences Ltd President & COO Eric Venker Sells 96,950 Shares (GuruFocus.com)
Jan-30-24 04:05PM	Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024 (GlobeNewswire)
Dec-27-23 08:05PM	5 High Growth International Stocks to Buy (Insider Monkey)
Dec-20-23 04:30PM	Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease (GlobeNewswire) -7.78% +5.82%
09:00AM	Loading…
Dec-14-23 09:00AM	Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease (GlobeNewswire)
Nov-28-23 07:00AM	Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential (GlobeNewswire)
02:38AM	5 Stocks Under $20 To Buy Now (Insider Monkey)
Nov-27-23 08:00AM	Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus (GlobeNewswire)
Nov-14-23 01:00PM	Roivant Sciences Ltd. (NASDAQ:ROIV) Q2 2023 Earnings Call Transcript (Insider Monkey)
Nov-13-23 07:00AM	Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update (GlobeNewswire)
Nov-10-23 08:00AM	Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors (GlobeNewswire)
Oct-30-23 05:30PM	Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023 (GlobeNewswire)
Oct-24-23 08:00AM	This $5 Billion Biotech Home Run Took Less Than a Year (The Wall Street Journal)
Oct-23-23 03:02PM	Roivant Sciences Sells Joint Venture With Pfizer to Roche for $7.1 Billion (Investopedia) -11.02%
10:31AM	Why Is Roivant Sciences (ROIV) Stock Up Today? (InvestorPlace)
09:52AM	Roche acquires Telavant, rights to bowel disease drug (Yahoo Finance Video)
06:55AM	Roche to Buy Bowel-Disease Drug From Roivant, Pfizer for More Than $7 Billion (The Wall Street Journal)
03:49AM	Roche to Buy Telavant From Roivant Sciences and Pfizer in $7.25 Bln Deal (The Wall Street Journal)
01:00AM	Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant (GlobeNewswire)
Oct-13-23 08:00AM	Covant Therapeutics Appoints Vincent Hennemand as Chief Executive Officer (GlobeNewswire)
Oct-05-23 05:01AM	Insider Sell: Eric Venker Sells 1,200,000 Shares of Roivant Sciences Ltd (ROIV) (GuruFocus.com) +5.04%
Oct-03-23 07:00AM	Vivek Ramaswamys Former Company Is Doing Just Fine Without Him (The Wall Street Journal)
Sep-30-23 05:00AM	Insider Sell: President & COO Eric Venker Sells 500,000 Shares of Roivant Sciences Ltd (ROIV) (GuruFocus.com)
Sep-26-23 06:00AM	Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results (GlobeNewswire) +21.55%
Sep-11-23 08:00AM	Roivant Announces Completion of Redemption of its Outstanding Warrants (GlobeNewswire) -8.65%
Sep-09-23 10:51AM	The Brash Strategy That Made Vivek Ramaswamy a Fortune (The Wall Street Journal)
Aug-17-23 04:05PM	Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding Warrants (GlobeNewswire)
Aug-14-23 07:00AM	Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business Update (GlobeNewswire)
Aug-03-23 04:05PM	Roivant to Report Financial Results for the Quarter Ended June 30, 2023, and Provide Business Update on Monday, August 14, 2023 (GlobeNewswire)
Aug-02-23 04:05PM	Roivant Announces Redemption of Outstanding Warrants (GlobeNewswire)
Jul-27-23 08:00AM	Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohns Disease (GlobeNewswire)
Jul-26-23 10:21AM	Big Short Steve Eisman Says the Stock Market Will Continue Surging as No Recession Signs Emerge Here Are 2 Stocks That Analysts Like (TipRanks)
Jul-13-23 05:50PM	Roivant in Talks to Sell Stomach Drug to Roche in Deal Valued at More Than $7 Billion (The Wall Street Journal)
Jul-11-23 08:00AM	Roivant Ranks No. 25 on Fast Companys Fifth Annual List of the 100 Best Workplaces for Innovators and is the Winner on the Science and Technology List as a Part of the Best Workplaces for Innovators Program (GlobeNewswire)
Jun-28-23 08:57AM	UPDATE -- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update (GlobeNewswire) +11.27%
07:00AM	Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update (GlobeNewswire)
Jun-26-23 04:05PM	Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provide Business Update on Wednesday, June 28, 2023 (GlobeNewswire) -6.33%
Jun-22-23 07:30AM	Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period (GlobeNewswire)
Jun-21-23 05:00PM	Roivant to Host Investor Call at 8:00 AM ET on Thursday, June 22 to Review Results from the Chronic Period of TUSCANY-2, a Large Global Phase 2b Study of RVT-3101 (Anti-TL1A Antibody) in Ulcerative Colitis (GlobeNewswire)
May-16-23 07:00AM	Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old (GlobeNewswire)
Apr-04-23 07:37AM	Lokavant Hires Experienced Leaders to Accelerate Growth Trajectory (Business Wire)
07:37AM	Lokavant Emerges from Roivant Sciences with Multiple Industry Partnerships to Accelerate Impact on Clinical Research (Business Wire)
Mar-28-23 08:00AM	Covant and Boehringer Ingelheim Collaborate to Develop a Novel ADAR1 Inhibitor for Use in Cancer Patients (GlobeNewswire)
Mar-15-23 07:45AM	Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old (GlobeNewswire) +7.91%
Mar-14-23 04:07PM	Roivant to Host Investor Call at 8:00 AM ET on Wednesday, March 15 to Review Results from ADORING 2 Phase 3 Trial in Atopic Dermatitis (GlobeNewswire)
08:00AM	Proteovant Therapeutics to Present Preclinical Data from Estrogen Receptor and IKZF2 Protein Degrader Programs (GlobeNewswire)
Mar-07-23 08:00AM	Covant Therapeutics Announces the Formation of its Scientific Advisory Board to Support Platform and Pipeline Advancement (GlobeNewswire)
Feb-21-23 08:32PM	Roivant Sciences Announces Change to its Board of Directors (GlobeNewswire)
Feb-13-23 04:17PM	Collecting Pharmas Scraps Can Pay Off for This Biotech (The Wall Street Journal) +7.77%
07:00AM	Roivant Sciences Reports Financial Results for the Third Quarter Ended December 31, 2022 and Provides Business Update (GlobeNewswire)
Feb-02-23 09:14PM	Roivant Sciences Announces Pricing of Upsized Public Offering of Common Shares (GlobeNewswire) -11.12%
Feb-01-23 04:05PM	Roivant Sciences Announces Proposed Public Offering of Common Shares (GlobeNewswire)
Jan-30-23 08:00AM	Roivant to Report Financial Results for the Third Quarter Ended December 31, 2022 on Monday, February 13, 2023 (GlobeNewswire)
Jan-04-23 06:05AM	Roivant Announces Statistically Significant and Clinically Meaningful Results from the Induction Period of TUSCANY-2, a Large Global Phase 2b Study of Subcutaneous RVT-3101 for the Treatment of Ulcerative Colitis in Both the Overall and the Biomarker Positive Patient Populations (GlobeNewswire) +5.73%
Dec-07-22 06:30AM	Edison Partners leads $21 million funding round for clinical trial intelligence disruptor Lokavant (PR Newswire)
Dec-01-22 08:00AM	Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases (GlobeNewswire) +8.21%
Nov-14-22 07:00AM	Roivant Sciences Reports Financial Results for the Second Quarter Ended September 30, 2022 and Provides Business Update (GlobeNewswire)
Nov-10-22 09:00AM	Affivant to Present Data on AFVT-2101 at 37th Annual Meeting of SITC (GlobeNewswire)
Nov-08-22 06:15AM	Roivant Sciences Announces Pricing of Primary and Secondary Public Equity Offering (GlobeNewswire) -11.19%
Nov-07-22 04:01PM	Roivant Sciences Announces Proposed Public Equity Offering (GlobeNewswire)
Oct-18-22 04:00PM	Roivant Sciences to Report Financial Results for the Second Quarter Ended September 30, 2022 on Monday, November 14, 2022 and Present at Upcoming Conferences (GlobeNewswire) -5.74%
Aug-30-22 07:00AM	Roivant to Participate in September Investor Events (GlobeNewswire)
Aug-16-22 11:44AM	Time To Worry? Analysts Are Downgrading Their Roivant Sciences Ltd. (NASDAQ:ROIV) Outlook (Simply Wall St.)
Aug-15-22 07:00AM	Roivant Sciences Reports Financial Results for the First Quarter Ended June 30, 2022 and Provides Business Update (GlobeNewswire)
Aug-14-22 10:53AM	Investors in Roivant Sciences (NASDAQ:ROIV) from a year ago are still down 56%, even after 16% gain this past week (Simply Wall St.)
Aug-03-22 07:00AM	Roivant Sciences to Report Financial Results for the Quarter Ended June 30, 2022 on Monday, August 15, 2022 (GlobeNewswire)
Jul-23-22 09:00AM	Roivant Sciences Ltd.'s (NASDAQ:ROIV) Intrinsic Value Is Potentially 34% Above Its Share Price (Simply Wall St.)
Jun-30-22 09:18AM	Roivant Sciences Ltd. (NASDAQ:ROIV) Analysts Are Cutting Their Estimates: Here's What You Need To Know (Simply Wall St.) -9.35%
Jun-28-22 06:27AM	Roivant, Pfizer unveil Priovant Therapeutics focused on autoimmune disease treatments, Roivant stock surges (MarketWatch)
06:10AM	Roivant Sciences Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 and Provides Business Update (GlobeNewswire)
06:00AM	Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus (GlobeNewswire)
Jun-15-22 04:30PM	Roivant Sciences to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 on Tuesday, June 28, 2022 (GlobeNewswire) +7.90% -5.21%
May-24-22 06:00AM	FDA Approves Dermavants VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical Novel Chemical Entity Launched for Psoriasis in the U.S. in 25 Years (GlobeNewswire) +7.12%
May-19-22 04:30PM	Roivant to Present at Upcoming Investor Conferences (GlobeNewswire)

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Venker Eric	President & COO	Oct 21 '24	Option Exercise	3.85	100,000	385,000	717,470	Oct 22 09:00 PM
Venker Eric	President & COO	Oct 21 '24	Sale	11.65	100,000	1,165,000	617,470	Oct 22 09:00 PM
Venker Eric	Officer	Oct 21 '24	Proposed Sale	11.65	100,000	1,165,393		Oct 21 04:45 PM
QVT Financial LP	Director by Deputization	Sep 26 '24	Sale	11.82	876,000	10,354,320	22,179,358	Sep 26 09:22 PM
QVT Financial LP	Director by Deputization	Sep 25 '24	Sale	11.77	50,000	588,500	23,055,358	Sep 26 09:22 PM
MANCHESTER KEITH S	Director	Sep 24 '24	Sale	11.62	368,052	4,278,604	1,412,126	Sep 26 08:35 PM
MANCHESTER KEITH S	Director	Sep 25 '24	Sale	11.77	134,948	1,587,704	1,277,178	Sep 26 08:35 PM
Gold Daniel Allen	Director	Sep 24 '24	Sale	11.62	1,565,670	18,200,914	5,723,423	Sep 26 08:34 PM
Gold Daniel Allen	Director	Sep 25 '24	Sale	11.77	991,593	11,666,389	4,731,830	Sep 26 08:34 PM
Gold Daniel Allen	Director	Sep 26 '24	Sale	11.82	876,000	10,354,320	22,179,358	Sep 26 08:34 PM
Gold Daniel Allen	Director	Sep 24 '24	Sale	11.62	577,186	6,709,787	2,079,059	Sep 26 08:34 PM
Gold Daniel Allen	Director	Sep 25 '24	Sale	11.77	415,551	4,889,317	1,713,508	Sep 26 08:34 PM
BNEI ZAHAV LLC	Director	Sep 25 '24	Proposed Sale	11.76	23,917	281,264		Sep 25 04:30 PM
RIOJA DOLCE LLC	Director	Sep 25 '24	Proposed Sale	11.76	170,817	2,008,808		Sep 25 04:25 PM
KEITH S MANCHESTER REVOCABLE T	Director	Sep 25 '24	Proposed Sale	11.76	134,948	1,586,988		Sep 25 04:23 PM
RIOJA LIETO LLC	Director	Sep 25 '24	Proposed Sale	11.76	170,817	2,008,808		Sep 25 04:20 PM
DANIEL GOLD & LAURA GOLD	Director	Sep 25 '24	Proposed Sale	11.76	991,593	11,661,134		Sep 25 04:19 PM
Gline Matthew	CEO	Sep 23 '24	Option Exercise	3.85	1,550,000	5,967,500	19,853,800	Sep 24 09:01 PM
Gline Matthew	CEO	Sep 23 '24	Sale	11.79	1,983,257	23,382,600	17,870,543	Sep 24 09:01 PM
Kumar Rakhi	Chief Accounting Officer	Sep 23 '24	Option Exercise	3.85	250,000	962,500	459,322	Sep 24 09:01 PM
Kumar Rakhi	Chief Accounting Officer	Sep 23 '24	Sale	11.89	250,000	2,972,500	209,322	Sep 24 09:01 PM
DANIEL GOLD &LAURA GOLD JT TEN	Director	Sep 24 '24	Proposed Sale	11.62	1,565,670	18,200,914		Sep 24 07:53 PM
RIOJA LIETO LLC	Director	Sep 24 '24	Proposed Sale	11.63	269,712	3,135,402		Sep 24 07:52 PM
RIOJA DOLCE LLC	Director	Sep 24 '24	Proposed Sale	11.63	269,712	3,135,402		Sep 24 07:51 PM
BNEI ZAHAV LLC	Director	Sep 24 '24	Proposed Sale	11.62	37,762	438,983		Sep 24 07:48 PM
KEITH S MANCHESTER REVOCABLE T	Director	Sep 24 '24	Proposed Sale	11.63	368,052	4,281,550		Sep 24 07:43 PM
Gline Matthew	Officer	Sep 23 '24	Proposed Sale	11.79	1,983,257	23,383,088		Sep 23 04:53 PM
Kumar Rakhi	Officer	Sep 23 '24	Proposed Sale	11.89	250,000	2,972,360		Sep 23 04:47 PM
Venker Eric	President & COO	Feb 09 '24	Option Exercise	3.85	96,950	373,258	629,157	Feb 09 09:00 PM
Venker Eric	President & COO	Feb 09 '24	Sale	10.92	96,950	1,058,694	532,207	Feb 09 09:00 PM
Ramaswamy Vivek	10% Owner	Jan 02 '24	Sale	11.05	3,000,000	33,150,000	51,929,426	Jan 03 04:56 PM

Open in Screener

ABUS

Arbutus Biopharma Corp

Oct 23 • 10:21AM ET

4.05

Dollar change +0.02
Percentage change 0.62	%

Healthcare • Biotechnology • USA • NASD

ABUS Arbutus Biopharma Corp daily Stock Chart

Peers: GILD REGN ALNY MRNA VRTX EXEL NBIX BMRN SRPT BLUE

| Held by: VTI IWM VXF XBI IWO IBB SCHA VTWO IWC ITOT

Index	RUT	P/E	-	EPS (ttm)	-0.44	Insider Own	22.31%	Shs Outstand	169.87M	Perf Week	-3.45%
Market Cap	765.50M	Forward P/E	-	EPS next Y	-0.35	Insider Trans	-0.02%	Shs Float	146.67M	Perf Month	0.87%
Income	-77.09M	PEG	-	EPS next Q	-0.09	Inst Own	51.24%	Short Float	5.02%	Perf Quarter	3.44%
Sales	10.06M	P/S	76.09	EPS this Y	12.27%	Inst Trans	20.89%	Short Ratio	6.54	Perf Half Y	47.45%
Book/sh	0.65	P/B	6.25	EPS next Y	9.33%	ROA	-45.77%	Short Interest	7.36M	Perf Year	139.94%
Cash/sh	0.75	P/C	5.39	EPS next 5Y	-	ROE	-59.96%	52W Range	1.69 - 4.72	Perf YTD	62.20%
Dividend Est.	-	P/FCF	-	EPS past 5Y	18.41%	ROI	-59.55%	52W High	-14.18%	Beta	1.91
Dividend TTM	-	Quick Ratio	6.56	Sales past 5Y	55.33%	Gross Margin	85.70%	52W Low	139.94%	ATR (14)	0.15
Dividend Ex-Date	-	Current Ratio	6.56	EPS Y/Y TTM	4.48%	Oper. Margin	-819.28%	RSI (14)	53.49	Volatility	3.98% 3.54%
Employees	73	Debt/Eq	0.06	Sales Y/Y TTM	-57.25%	Profit Margin	-766.20%	Recom	1.40	Target Price	5.00
Option/Short	Yes / Yes	LT Debt/Eq	0.06	EPS Q/Q	-2.33%	Payout	-	Rel Volume	0.46	Prev Close	4.03
Sales Surprise	-2.29%	EPS Surprise	-14.58%	Sales Q/Q	-62.89%	Earnings	Aug 01 BMO	Avg Volume	1.13M	Price	4.05
SMA20	3.20%	SMA50	1.21%	SMA200	25.37%	Trades		Volume	90,351	Change	0.62%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-02-22	Upgrade	Jefferies	Hold → Buy	$5
Feb-25-21	Initiated	Jefferies	Hold	$5
Dec-17-20	Initiated	H.C. Wainwright	Buy	$10
Jul-27-20	Resumed	JMP Securities	Mkt Outperform	$10 → $8
Jul-24-20	Downgrade	Robert W. Baird	Outperform → Neutral
May-19-20	Upgrade	Wedbush	Neutral → Outperform
Mar-06-20	Upgrade	Chardan Capital Markets	Neutral → Buy	$5
Feb-20-20	Initiated	Robert W. Baird	Outperform	$8
Feb-05-20	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform	$10
Oct-07-19	Reiterated	B. Riley FBR	Buy	$7 → $3
Oct-04-19	Downgrade	Chardan Capital Markets	Buy → Neutral
Oct-16-18	Upgrade	B. Riley FBR	Neutral → Buy	$11.50 → $9
Oct-15-18	Upgrade	Wedbush	Underperform → Neutral	$5
Oct-12-18	Reiterated	Chardan Capital Markets	Buy	$12 → $6.50
Jul-06-18	Downgrade	B. Riley FBR, Inc.	Buy → Neutral	$9 → $9
Mar-19-18	Resumed	Chardan Capital Markets	Buy	$8.25
Mar-19-18	Downgrade	Wedbush	Outperform → Neutral	$9 → $6
Jan-05-18	Initiated	B. Riley FBR, Inc.	Buy	$10
Apr-04-17	Upgrade	Chardan Capital Markets	Neutral → Buy	$3 → $6
Feb-01-17	Reiterated	Wedbush	Outperform	$13 → $10

Show Previous Ratings

Today 07:30AM	Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update (GlobeNewswire)
Oct-15-24 08:16AM	Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting 2024 (GlobeNewswire) +6.48%
Oct-01-24 07:30AM	Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference (GlobeNewswire)
Sep-25-24 09:40AM	Has Arbutus Biopharma (ABUS) Outpaced Other Medical Stocks This Year? (Zacks)
Sep-03-24 07:30AM	Arbutus to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
09:40AM	Loading…
Aug-22-24 09:40AM	Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-06-24 09:40AM	Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year? (Zacks)
Aug-02-24 01:51AM	Q2 2024 Arbutus Biopharma Corp Earnings Call (Thomson Reuters StreetEvents)
Aug-01-24 08:40AM	Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:41AM	Arbutus: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-18-24 07:30AM	Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update (GlobeNewswire)
Jun-06-24 11:15AM	Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels (GlobeNewswire) -7.99%
11:15AM	Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B (GlobeNewswire)
Jun-05-24 02:30AM	Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure (GlobeNewswire) +8.68%
07:30AM	Loading…
May-29-24 07:30AM	Arbutus to Participate in Jefferies Global Healthcare Conference (GlobeNewswire)
May-22-24 02:00AM	Arbutus to Present Imdusiran Data at EASL Congress 2024 (GlobeNewswire) +6.23%
May-17-24 12:03PM	Update: Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program (MT Newswires)
10:40AM	Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program (MT Newswires)
09:00AM	Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value (Business Wire)
May-07-24 07:30AM	Arbutus to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
May-03-24 11:19AM	Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:24AM	Arbutus Biopharma Corp (ABUS) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-02-24 12:55PM	ABUS Stock Earnings: Arbutus Biopharma Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:58AM	Arbutus Biopharma Corp Reports Q1 2024 Earnings: A Detailed Financial Review (GuruFocus.com)
08:45AM	Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:44AM	Arbutus: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
07:25AM	Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024 (GlobeNewswire)
Apr-30-24 09:40AM	Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year? (Zacks)
07:30AM	Loading…
Apr-18-24 07:30AM	Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update (GlobeNewswire)
Apr-04-24 08:30AM	Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna (GlobeNewswire)
Mar-08-24 07:30AM	Arbutus to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Mar-01-24 08:17AM	Arbutus Biopharma Corporation (NASDAQ:ABUS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-29-24 11:14PM	Q4 2023 Arbutus Biopharma Corp Earnings Call (Thomson Reuters StreetEvents)
08:40AM	Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:52AM	Arbutus Biopharma Corp (ABUS) Reports Year-End Financial Results and Progress in Clinical Trials (GuruFocus.com)
07:30AM	Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-15-24 07:30AM	Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update (GlobeNewswire)
Jan-08-24 07:30AM	Arbutus Announces 2024 Corporate Objectives and Provides Financial Update (GlobeNewswire)
Nov-09-23 04:24PM	Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD (GlobeNewswire)
04:01PM	Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting (GlobeNewswire)
09:12AM	Arbutus Biopharma Corporation (NASDAQ:ABUS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 07:30AM	Arbutus to Present at Jefferies London Healthcare Conference (GlobeNewswire)
01:16AM	Q3 2023 Arbutus Biopharma Corp Earnings Call (Thomson Reuters StreetEvents)
Nov-07-23 08:05AM	Arbutus Biopharma Corp (ABUS) Reports Q3 2023 Financial Results (GuruFocus.com)
07:40AM	Arbutus: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
07:15AM	Arbutus Announces CEO, William Collier, to Retire December 31, 2023 (GlobeNewswire)
Oct-30-23 09:32AM	12 Best Micro Cap Stocks To Invest In (Insider Monkey)
Oct-24-23 07:30AM	Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update (GlobeNewswire)
Oct-18-23 07:30AM	Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference (GlobeNewswire) -5.82%
Oct-11-23 08:05AM	Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting 2023 (GlobeNewswire)
Sep-12-23 10:56AM	Arbutus BioPharma narrows research focus to extend cash runway (American City Business Journals) -7.73%
08:58AM	Arbutus (ABUS) to Focus on Hepatitis B Candidates, Stock Up (Zacks)
Sep-11-23 04:15PM	Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended (GlobeNewswire)
Sep-07-23 07:30AM	Arbutus to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-04-23 03:29PM	Arbutus Biopharma Corporation (NASDAQ:ABUS) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-03-23 08:55AM	Arbutus Biopharma (ABUS) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:49AM	Arbutus: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update (GlobeNewswire)
Jul-23-23 10:19AM	Arbutus Biopharma Corporation (NASDAQ:ABUS) has caught the attention of institutional investors who hold a sizeable 38% stake (Simply Wall St.)
Jul-20-23 07:30AM	Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate Update (GlobeNewswire)
Jul-12-23 07:30AM	Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors (GlobeNewswire)
Jul-10-23 04:01PM	Arbutus Appoints Two New Executives (GlobeNewswire)
Jun-23-23 09:40AM	Are Medical Stocks Lagging Amphastar Pharmaceuticals (AMPH) This Year? (Zacks)
Jun-21-23 07:30AM	Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody (GlobeNewswire)
02:01AM	Arbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023 (GlobeNewswire)
Jun-07-23 09:40AM	Is Amphastar Pharmaceuticals (AMPH) Stock Outpacing Its Medical Peers This Year? (Zacks)
02:01AM	Arbutus to Present AB-729 and AB-836 Data at EASL Congress 2023 (GlobeNewswire)
Jun-01-23 11:29AM	Biohaven (BHVN) Stock up 8% on Encouraging Pipeline Updates (Zacks)
May-31-23 07:30AM	Arbutus to Present at Jefferies Healthcare Conference (GlobeNewswire)
May-30-23 09:26AM	Valneva (VALN) Stock Down 53% in the Past Year: Here's Why (Zacks)
May-29-23 10:08AM	FDA Accepts Iovance's (IOVA) BLA Filing for Melanoma Drug (Zacks)
May-22-23 09:40AM	Is Amphastar Pharmaceuticals (AMPH) Outperforming Other Medical Stocks This Year? (Zacks)
May-17-23 07:38AM	Here's Why We're Watching Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Situation (Simply Wall St.)
May-09-23 12:00PM	Arbutus (ABUS) Upgraded to Buy: Here's Why (Zacks)
07:30AM	Arbutus to Present at JMP Securities Life Sciences Conference (GlobeNewswire)
May-04-23 11:52PM	Q1 2023 Arbutus Biopharma Corp Earnings Call (Thomson Reuters StreetEvents)
09:40AM	Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year? (Zacks)
08:55AM	Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Arbutus Reports First Quarter 2023 Financial Results and Corporate Update (GlobeNewswire)
Apr-27-23 03:20AM	Arbutus Provides AB-729 Clinical Data and AB-161 Preclinical Data as Oral Presentations at the Global Hepatitis Summit 2023 (GlobeNewswire)
Apr-25-23 11:57AM	Why Arbutus Biopharma Stock Is Plunging Today (Benzinga) -12.46%
11:50AM	Why Arbutus Biopharma Stock Is Sinking Today (Motley Fool)
07:30AM	Arbutus Announces FDA Clinical Hold on IND Application for AB-101, an oral PD-L1 inhibitor (GlobeNewswire)
Apr-20-23 07:30AM	Arbutus to Report First Quarter 2023 Financial Results and Provide Corporate Update (GlobeNewswire)
Apr-18-23 04:01PM	Arbutus to Present AB-729 and AB-161 Data at the Global Hepatitis Summit 2023 (GlobeNewswire)
02:18PM	Arbutus Biopharma Corporation's (NASDAQ:ABUS) Share Price Could Signal Some Risk (Simply Wall St.)
Apr-12-23 12:37PM	US Court Favors Moderna In COVID-19 Vaccine Patent Infringement Case With Arbutus Biopharma (Benzinga)
Apr-11-23 03:30PM	UPDATE 1-Moderna fends off Arbutus appeal in COVID-19 vaccine patent fight (Reuters)
01:00PM	Moderna fends off Arbutus appeal in COVID-19 vaccine patent fight (Reuters)
Apr-04-23 04:08PM	Pfizer Slapped With Additional Patent Infringement Lawsuit Over Its Famed COVID-19 Shots (Benzinga)
08:22AM	UPDATE 2-Arbutus files patent infringement lawsuit against Pfizer/BioNTech over COVID shots (Reuters)
08:17AM	Arbutus files patent lawsuit against Pfizer/BioNTech over COVID vaccines (Reuters)
07:52AM	Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Pfizer/BioNTech (GlobeNewswire)
Mar-24-23 12:29PM	Lab Notes: Arbutus begins human testing of potential hepatitis B cure (American City Business Journals)
Mar-19-23 10:17AM	Those who invested in Arbutus Biopharma (NASDAQ:ABUS) three years ago are up 108% (Simply Wall St.)
Mar-16-23 07:30AM	Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161 (GlobeNewswire)
Mar-14-23 04:05PM	Arbutus Presents AB-343 Data at the 36th International Conference on Antiviral Research (GlobeNewswire)

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the Hepatitis B virus, SARS-CoV-2, and other coronaviruses. The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MANCHESTER KEITH S	Director	Aug 14 '24	Option Exercise	0.56	54,915	30,752	54,915	Aug 16 04:07 PM
MANCHESTER KEITH S	Director	Aug 14 '24	Sale	3.69	8,846	32,637	46,069	Aug 16 04:07 PM
Sims Karen	Chief Medical Officer	Feb 02 '24	Sale	2.31	4,358	10,078	125,542	Feb 05 07:55 PM
HASTINGS DAVID C	Chief Financial Officer	Feb 02 '24	Sale	2.31	9,593	22,184	181,907	Feb 05 07:54 PM
Sofia Michael J.	Chief Scientific Officer	Feb 02 '24	Sale	2.31	9,982	23,083	1,485,121	Feb 05 07:54 PM
McElhaugh Michael J.	Interim President & CEO	Feb 02 '24	Sale	2.31	10,164	23,504	1,504,793	Feb 05 07:54 PM

ROIV

Roivant Sciences Ltd

ABUS

Arbutus Biopharma Corp

Upgrade your FINVIZ experience